Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EBMT 2020 | CD5 and CD7 directed CAR T-cells for pediatric T-cell malignancies

Maksim Mamonkin • 1 Sep 2020
EBMT 2020
Acute Lymphoblastic Leukemia Leukemia Lymphoma T-Cell Lymphoma Antibodies CAR-T
MAGENTA

Maksim Mamonkin, PhD, Baylor College of Medicine, Houston, TX, outlines the use of CD5 and CD7 directed CAR T-cells for pediatric T-cell malignancies, including the results of the first-in-man study of CD5 CAR T-cells in the treatment of T-cell malignancies, as well as challenges associated with bringing these innovative therapies to the clinic. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Maksim Mamonkin

Using engineered T-cells to suppress acute GvHD and leukemia relapse after alloSCT 2:05
Using engineered T-cells to suppress acute GvHD and leukemia relapse after alloSCT
Maksim Mamonkin • 10 Feb 2023
CAR-T cell therapy for T-cell malignancies: challenges to address and future outlooks 1:51
CAR-T cell therapy for T-cell malignancies: challenges to address and future outlooks
Maksim Mamonkin • 10 Feb 2023
Exploring the potential role of CD7-targeting CAR-T cells for the treatment of T-ALL 2:14
Exploring the potential role of CD7-targeting CAR-T cells for the treatment of T-ALL
Maksim Mamonkin • 10 Feb 2023
Resisting immune rejection: engineered off-the-shelf T-cells 4:14
Resisting immune rejection: engineered off-the-shelf T-cells
Maksim Mamonkin • 20 Aug 2020

Related Videos

A retrospective study of Pola-R-CHP versus R+DA-EPOCH in high-risk DLBCL 1:58
A retrospective study of Pola-R-CHP versus R+DA-EPOCH in high-risk DLBCL
Rahul Thakur • 8 Dec 2025
Extended follow-up from a Phase I/II study of golcadomide ± rituximab in patients with R/R DLBCL 1:35
Extended follow-up from a Phase I/II study of golcadomide ± rituximab in patients with R/R DLBCL
Marc Hoffman • 7 Dec 2025
Epcoritamab + R2 or epcoritamab maintenance in 1L FL: 3-year outcomes from EPCORE NHL-2 arms 6 & 7 2:53
Epcoritamab + R2 or epcoritamab maintenance in 1L FL: 3-year outcomes from EPCORE NHL-2 arms 6 & 7
Lori Leslie • 7 Dec 2025
Genomic assessment of acquired mutations in patients with CLL treated with nemtabrutinib 3:37
Genomic assessment of acquired mutations in patients with CLL treated with nemtabrutinib
Thomas Kipps • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals